Claudin-1 showed a trend to elevation in the tumor tissues of C150-treated mice but the change was not statistically significant, whereas the pro-metastasis marker MMP-2 trended to decrease with C150 treatment (Figures 5E, F). This evidence concerns the gene CLDN1 and neoplasm.